Medication Related Osteonecrosis of the Jaw
Conditions
Brief summary
BETCON is a pragmatic randomized controlled open-label multi-center study in patients with newly diagnosed stage I-II MRONJ designed to answer the question whether minimally invasive management with LPRF membranes or primary surgical treatment is better than the standard of care of conservative therapy alone. The primary end-point is the time to mucosal healing. Secondary end-points consist of supporting measures of efficacy, patient reported symptoms, quality of life, well-being, and functioning.
Detailed description
While effective for symptom control and well tolerated, conservative treatment of MRONJ yields highly variable mucosal healing rates ranging between 20 to 50%. In an effort to improve these suboptimal outcomes, many adjunct treatment modalities have been studied, of which the use of minimally invasive surgery with autologous platelet rich plasma (LPRF) to improve wound healing has attracted considerable attention, with reported mucosal closure rates of up to 86% in single arm case series. More recently, improved understanding of the need for pre-operative infection control and adaptation of surgical protocols has renewed the interest in the primary surgical treatment of MRONJ with mucosal closure achieved in up to 90% of patients in some case series. Therapeutic studies of MRONJ have almost exclusively focused on mucosal healing as the desired end-point of MRONJ treatment, with little or no attention to patient symptoms, quality of life, functioning and well-being during treatment, even though the resolution of MRONJ symptoms and limiting treatment related adverse events may be equally important to patients. This comparative effectiveness research (CER) study is a randomized controlled open-label multi-center study in patients with newly diagnosed stage I-II MRONJ and is designed to answer the question whether minimally invasive treatment with LPRF membranes or primary surgical treatment improves outcomes when added to the standard of care of conservative treatment alone. The study also incorporates pragmatic design elements and uses patient reported outcomes (PRO) to determine which treatment offers the best humanistic outcomes considering both efficacy and measures of quality of life, functioning, well-being and symptom control. Indeed, this study will not use an investigational new drug (or drug regimen), device, or surgical technique, but rather evaluate their relative efficacy to guide future clinical management. Finally, plasma and saliva will be collected to identify prognostic and predictive biomarkers of outcome.
Interventions
DRUGChlorhexidine mouthwash
Patients in all treatment groups will be prescribed aqueous chlorhexidine 0.12% tid rinse for 2 weeks, with subsequent switch to 0.05% for the duration of the study or until healing of the MRONJ lesion has occurred.
PROCEDUREMinimally invasive surgery with LPRF
Minimally-invasive surgical treatment, including sequestrectomy, debridement of soft tissue, and application of LPRF membranes before tension-free wound closure is obtained. Marginal resection of all necrotic bone is not part of this treatment strategy.
PROCEDURESurgical resection
Primary surgical management consisting of the removal of the necrotic bone without excessive resection of healthy bone. Buccal mucoperiosteal flaps will be used to achieve a tension-free mucosal coverage.
DRUGAntibiotics
Antibiotic treatment is the same in all groups. Monotherapy for 4 weeks with: No penicillin contra-indication * Amoxicillin-clavulanate 875mg tid PO Penicillin contra-indication or intolerance * Clindamycin 300mg tid PO After 4 weeks patients will be switched to consolidation antibiotics: No penicillin contra-indication * Amoxicillin 1g bid PO Penicillin contra-indication or intolerance * Clindamycin 300mg tid PO Antibiotic treatment can be discontinued after 4 weeks when the MRONJ lesions has healed.
Sponsors
Kom Op Tegen Kanker
Tim Van den Wyngaert
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \>18 years of age * Provision of signed informed consent * A history of at least one administration of, or an ongoing treatment with, a bone modifying agent in dose registered for the prevention of skeletal related events in bone metastatic disease or multiple myeloma * Diagnosis of stage I-II MRONJ according to AAOMS 2014 criteria not more than 8 weeks prior to the date of screening
Exclusion criteria
* Any prior treatment for MRONJ other than local antiseptic rinses, systemic antibiotics, or analgesics * Prior radiotherapy to the head and neck region * Medical contraindication to receive any of the possible study treatments * Stage III MRONJ characterized by very extensive bone necrosis, pathological fracture, or fistulas to the skin or sinuses * Multiple MRONJ lesions that cannot be closed in a single surgical procedure
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to confirmed mucosal healing | 12 months | Time after randomization until the observation of healed mucosa (without presence of surgical suturing material) at the site of MRONJ, with a first observation of healed mucosa requiring confirmation after 4 weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to MRONJ healing | 12 months | Time to resolution of MRONJ symptoms after start of treatment |
| Relapse rate of MRONJ | 12 months | Incidence of patients with relapse at the site of MRONJ |
| Antibiotics use | 12 months | Total duration of exposure to antimicrobial agents |
| Evolution of cancer health-related quality-of-life | 12 months | Changes over time as measured with the EORTC QLQ-C30 questionnaire. |
| Evolution of general health status | 12 months | Changes over time as measured with the EUROQOL 5D (EQ-5D-5L) questionnaire. |
| Evolution of oral health-specific quality-of-life | 12 months | Changes over time as measured with the Oral Health Impacts Profile (OHIP-14) and the SWOG0702 Oral Health and Oral Health-related Quality of Life questionnaires. |
| Mucosal closure | 6 months | Proportion of patients with mucosal closure 6 months after randomization |
Other
| Measure | Time frame | Description |
|---|---|---|
| Treatment related adverse events | Through study completion, an average of 1 year | Incidence and intensity of treatment emergent adverse events |
| Quality-adjusted Time Without Symptoms and Toxicity (Q-TWiST) | Through study completion, an average of 1 year | This analysis analysis considers three health states: toxicity, time without symptoms and toxicity (TWiST), and relapse. The toxicity state comprises the total time after randomization and before relapse of MRONJ symptoms spent with toxicity, regardless of when the toxicity started or gaps between toxicities. The TWiST state is defined as the time of relapse of MRONJ symptoms minus time with toxicities. The duration of the relapse state is defined as overall survival time minus time to relapse of MRONJ symptoms. |
Countries
Belgium
Contacts
Primary ContactTim Van den Wyngaert, MD, PhD
Outcome results
None listed